An Open-Label Functionality, Safety, and Efficacy Study of the NanoTab Delivery System/ARX-F01 15 Mcg in Patients Undergoing Elective Unilateral Knee Replacement.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc
18 May 2011 Combined results from this and two other trials (NCT00612534 and NCT00718081) presented at the 30th Annual Scientific Meeting of the American Pain Society, according to a AcelRx Pharmaceuticals media release.
20 Apr 2010 Actual number of patients and trial centres updated, as reported by an AcelRx Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com